SCHEMBL3325660

SCHEMBL3325660

COC(=O)C1=C(C)NC2=C(C(=O)CC(c3ccccc3)C2)C1c1cc(OC)ccc1OC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.57
POLB P06746 3/20 0.55
HSD17B10 Q99714 2/20 0.55
TP53 P04637 1/20 0.55
ALDH1A1 P00352 7/20 0.52
USP2 O75604 3/20 0.52
MAPK1 P28482 2/20 0.52
RAB9A P51151 1/20 0.52
HPGD P15428 5/20 0.49
NPSR1 Q6W5P4 4/20 0.49
CYP3A4 P08684 3/20 0.49
CYP2C19 P33261 3/20 0.49
CYP2C9 P11712 2/20 0.49
MAPT P10636 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
CYP1A2 P05177 2/20 0.49
CYP2D6 P10635 1/20 0.49
MC4R P32245 1/20 0.49
TSHR P16473 2/20 0.49
CASP1 P29466 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3329266 0.92 KDM4E (0.69) KDM4EPOLBHSD17B10TP53ALDH1A1
SCHEMBL13096483 0.87 ALDH1A1 (0.56) KDM4EPOLBHSD17B10ALDH1A1USP2
SCHEMBL3320594 0.86 KDM4E (0.66) KDM4EPOLBHSD17B10TP53ALDH1A1
SCHEMBL30938379 0.85 PKM (0.51) KDM4EPOLBHSD17B10TP53ALDH1A1
SCHEMBL30938449 0.85 PKM (0.51) KDM4EPOLBHSD17B10TP53ALDH1A1
SCHEMBL3324856 0.84 ALDH1A1 (0.61) KDM4EPOLBHSD17B10TP53ALDH1A1
SCHEMBL14508415 0.84 KDM4E (0.62) KDM4EPOLBHSD17B10ALDH1A1USP2
SCHEMBL3323418 0.84 KDM4E (0.57) KDM4EPOLBHSD17B10TP53ALDH1A1
SCHEMBL30938421 0.84 PKM (0.56) KDM4EPOLBHSD17B10ALDH1A1USP2
SCHEMBL30938436 0.84 PKM (0.56) KDM4EPOLBHSD17B10ALDH1A1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION ARCHER PHARMACEUTICALS, INC. (US) 2010-05-13 US disclosed
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION ARCHER PHARMACEUTICALS, INC. (US) 2010-05-13 US disclosed
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION ARCHER PHARMACEUTICALS, INC. (US) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION APP, MAPT, PSEN1 KDM4E 4115/4885POLB 606/4885HSD17B10 1530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.